Latest & greatest articles for Galantamine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Galantamine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Galantamine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Galantamine

21. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis

A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

22. Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries

Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries Caro J, Salas M, Ward A, Getsios D (...) , Migliaccio-Walle K, Garfield F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Galantamine was compared with placebo for the treatment of Alzheimer's disease in seven health care systems. Type of intervention Treatment. Economic study

2004 NHS Economic Evaluation Database.

23. Effect of galantamine hydrobromide in chronic fatigue syndrome: a randomized controlled trial. (PubMed)

Effect of galantamine hydrobromide in chronic fatigue syndrome: a randomized controlled trial. There is no established pharmacological treatment for the core symptoms of chronic fatigue syndrome (CFS). Galantamine hydrobromide, an acetyl cholesterone inhibitor, has pharmacological properties that might benefit patients with CFS.To compare the efficacy and tolerability of galantamine hydrobromide in patients with CFS.Randomized, double-blind trial conducted June 1997 through July 1999 at 35 (...) outpatient centers in the United Kingdom (n = 17), United States (n = 14), the Netherlands (n = 2), Sweden (n = 1), and Belgium (n = 1) involving 434 patients with a clinical diagnosis of CFS (modified US Centers for Disease Control and Prevention criteria).A total of 89 patients were randomly assigned to receive 2.5 mg of galantamine hydrobromide; 86 patients, 5.0 mg; 91 patients, 7.5 mg; and 86 patients, 10 mg (these patients received medicine in the tablet form 3 times per day); a total of 82 patients

Full Text available with Trip Pro

2004 JAMA Controlled trial quality: predicted high

24. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK

Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 NHS Economic Evaluation Database.

25. Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia

Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia Fajemisin B Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Fajemisin B. Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia. London: Bazian Ltd (Editors), Wessex Institute for Health Research and Development, University of Southampton 2002: 9 Authors' objectives This study aims to assess the effects of acetylcholinesterase inhibitors (donepezil, rivastigmine, tacrine, galantamine) on functional outcomes in people with non-Alzheimer's dementia. Authors' conclusions We found

2002 Health Technology Assessment (HTA) Database.

26. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. (PubMed)

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Vascular dementia is the second commonest form of dementia, and vascular factors contribute to the development of dementia in many patients with Alzheimer's disease. Galantamine amplifies the acetylcholine response by inhibiting acetylcholinesterase and modulating nicotinic receptors. It has shown broad, sustained benefits in patients with Alzheimer's disease (...) . We investigated the effects of galantamine in patients with a diagnosis of probable vascular dementia or Alzheimer's disease combined with cerebrovascular disease.Eligible patients were randomly assigned galantamine 24 mg/day (n=396) or placebo (n=196) in a multicentre, double-blind, 6-month trial. Primary endpoints were cognition (Alzheimer's disease assessment scale, cognitive subscale [ADAS-cog]) and global functioning (clinician's interview-based impression of change plus caregiver input

2002 Lancet Controlled trial quality: predicted high

27. Galantamine for Alzheimer's disease. (PubMed)

Galantamine for Alzheimer's disease. Galantamine (also called galanthamine, marketed as Reminyl (Janssen)) was isolated from several plants, including daffodil bulbs, but is now synthesized. Galantamine is a specific, competitive, and reversible acetylcholinesterase inhibitor. It is also an allosteric modulator at nicotinic cholinergic receptor sites potentiating cholinergic nicotinic neurotransmission. A small number of early studies showed mild cognitive and global benefits for patients (...) with Alzheimer's disease (AD), and recently several multicenter clinical trials have been published with positive findings. Galantamine has received regulatory approval in 29 counties: Argentina, Australia, Canada, Czechia, the European Union (except for The Netherlands), Iceland, Korea, Mexico, Norway, Poland, Singapore, South Africa, Switzerland, Thailand, and the United States.The objective of this overview is to assess the clinical effects of galantamine in patients with probable AD, and to investigate

2001 Cochrane

28. Clinical and cost-effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review

Clinical and cost-effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review Clinical and cost-effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review Clinical and cost-effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N Authors' objectives To provide a rapid (...) and systematic review of the clinical effectiveness and cost-effectiveness of donepezil, rivastigmine and galantamine in the symptomatic treatment of people suffering from Alzheimer's disease (AD). Searching The following databases were searched from their inception to March to July, 2000: MEDLINE, EMBASE, the Cochrane Library, DARE, NHS EED, the National Researh Register, the Science Citation Index, BIOSIS Previews, EconLit, the MRC Clinical Trials Directory, an Early Warning System database, Current

2001 DARE.

29. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease

Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation National Institute for Clinical Excellence. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 19. 2001 Authors' objectives To provide guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. Authors' conclusions Guidance 1.1 The three drugs donepezil, rivastigmine

2001 Health Technology Assessment (HTA) Database.

30. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review

Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review. Health Technology Assessment 2001; 5(1): 1-137 Authors' objectives To provide a rapid and systematic review of the clinical

2001 Health Technology Assessment (HTA) Database.

31. Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada

Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada Getsios D, Caro J J, Caro G, Ishak K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of galantamine, a cholinesterase inhibitor, to restore cognitive ability or to slow cognitive deterioration in patients with Alzheimer's disease (AD). Galantamine also has a modulating effect on nicotinic receptors. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients

2001 NHS Economic Evaluation Database.

32. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. (PubMed)

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. To evaluate the efficacy and safety of galantamine in the treatment of Alzheimer's disease.Randomised, double blind, parallel group, placebo controlled trial.86 outpatient clinics in Europe and Canada.653 patients with mild to moderate Alzheimer's disease.Patients randomly assigned to galantamine had their daily dose (...) escalated over three to four weeks to maintenance doses of 24 or 32 mg.Scores on the 11 item cognitive subscale of the Alzheimer's disease assessment scale, the clinician's interview based impression of change plus caregiver input, and the disability assessment for dementia scale. The effect of apolipoprotein E4 genotype on reponse to treatment was also assessed.At six months, patients who received galantamine had a significantly better outcome on the 11 item cognitive subscale of the Alzheimer's

Full Text available with Trip Pro

2000 BMJ Controlled trial quality: predicted high

33. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review

Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review Journals Library Journals Library An error has occurred in processing the XML document An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search

2000 NIHR HTA programme